

COVID Primary care Collaborative

12/8/2020

Close contact

Someone who was within 6 feet of an infected person for a cumulative total of 15 minutes or more over a 24-hour period* starting from 2 days before illness onset (or, for asymptomatic patients, 2 days prior to test specimen collection) until the time the patient is isolated.

(CDC, Oct 21, 2020)

Quarantine Guidance

For a COVID case

- Follow the 10/1 rule

For a COVID contact

- SAFEST: 14 days from time of last exposure
- NEW (*CDC 12/4*):
 - 10 days of quarantine have been completed AND no symptoms have been reported during daily monitoring
 - 7 days of quarantine have been completed AND no symptoms have been reported during daily monitoring AND a diagnostic specimen tests negative within 48 hours of the planned quarantine discontinuation (no earlier than day 5 after last contact)

COVID-19 Testing Updates

Local turnaround time 2-7 days.

Major Types of Testing Available:

RT-PCR/Nucleic Acid

*gold standard

Viral Antigen


Viral Antibody

(not for diagnosis of acute illness)

Table 1. Summary of Some Differences between NAATs and Antigen Tests

	Nucleic Acid Amplification Tests	Antigen Tests
Intended Use	Detect current infection	Detect current infection
Analyte Detected	Viral Ribonucleic Acid (RNA)	Viral Antigens
Specimen Type(s)	Nasal, Nasopharyngeal, Sputum, Saliva	Nasal, Nasopharyngeal
Sensitivity	Varies by test, but generally high	Moderate
Specificity	High	High
Test Complexity	Varies by Test	Relatively Easy to Use
Authorized for Use at the Point-of-Care	Most are not, some are	Most are, some are not
Turnaround Time	Ranges from 15 minutes to >2 days	Ranges from 15 minutes to >2 days
Cost/Test	Moderate (~\$100/test)	Low (~\$5-50/test)

Using, Interpreting, & Responding to COVID-19 Antigen Tests



¹Close contact/known exposure is defined as within 6 feet of someone known to have COVID-19 for 15 minutes or longer over a 24-hour period.

²While multiple specimen types may be acceptable, if possible, confirmatory tests should be performed using specimens with evidence of the most sensitivity, such as nasopharyngeal or mid-turbinate swabs.

³A PCR test in a CLIA certified laboratory is recommended for individuals whose symptom onset is greater than 7 days. A negative result on an antigen test performed on a symptomatic individual greater than 7 days from onset should be confirmed with a PCR test. A positive antigen test result on a symptomatic individual greater than 7 days from onset does not require PCR confirmation.

⁴A positive antigen result in an asymptomatic, unexposed individual should be immediately followed by a PCR test in a CLIA certified laboratory to verify the positive result. This follow-up specimen should be collected within 24 hours of the original test, if possible; and no more than 48 hours after the antigen test. Specimens collected greater than 48 hours after the initial test may lead to discordant results. If the confirmatory PCR is negative on an appropriate specimen collected in the proper timeframe and the individual has remained asymptomatic, the individual should isolate per NCDHHS guidance.

⁵If confirmatory PCR testing is not performed, the individual should isolate per NCDHHS guidance.

NOTE: For antigen tests performed in the nursing home setting, see CDC's Considerations for Antigen Testing in Long-Term Care Facilities.



1 / 1




NC DEPARTMENT OF
HEALTH AND
HUMAN SERVICES

www.ncdhhs.gov • NCDHHS is an equal
opportunity employer and provider. • 11/20



COVID Vaccine Mechanisms


Three types of coronavirus vaccines in development





COVID Vaccines: A New Hope

	mRNA-1273	mRNA-BNT162b2	AZD1222	JNJ-78436735	NVX- CoV2373
Manufacturer	Moderna/NIAID	Pfizer/BioNTech	Astra Zeneca	Janssen (J&J)	Novovax
Vaccine technology	mRNA	mRNA	Recombinant adenovirus vector	Recombinant adenovirus vector	Protein subunit
Frozen	Store at -20 C	Store at -70 C	N/A	Store at -20 C	N/A
Refrigeration	Stable for 30d	Use within 5d	Until expiration date	Stable for 3 months	Store under refrigeration
Dosing	2 doses, 28 days apart	2 doses, 21 days apart	2 doses, 28 days apart	1 dose	2 doses, 21 days apart
Manufacturing Speed	Fast	Fast	Medium	Medium	Medium to fast
Phase 3 data available	Interim analysis	Interim analysis	Interim analysis	No	No





Interim Analysis Reported Data (by Press Release)

- mRNA-1273
 - Reported efficacy 94.5%
 - 5 COVID cases in vaccine arm (no severe cases)
 - 90 cases in placebo (11 severe)
- mRNA- BNT162b2
 - reported efficacy 95%
 - 94 COVID cases in the trial
- AZD1222
 - Reported efficacy 90% when ½ dose given day 1 and full dose day 28 (2741 participants)
 - Reported efficacy 62% when full dose day 1 and 28 (8895 participants)
 - Combined efficacy 70%